-
公开(公告)号：WO2018157230A1
公开(公告)日：2018-09-07
申请号：PCT/CA2017/050531
申请日：2017-05-02
Applicant: HAMILTON, Matthew
Inventor： HAMILTON, Matthew , CAMPBELL-CORREA, Jennifer , HILL, Stephen , PECKHAM, Jordan , RUMBOLT, Chuck , HAAS, Wally
Abstract: The present disclosure relates to a directional pixel for a high-angular resolution, wide field of view, multiple view display. The design teaches a directional pixel comprising a substrate, one or more pixel driving circuits, one or more nano- or micro-scale subpixels, and one or more directional optical guiding surfaces, wherein each of said one or more subpixels is comprised of a light emitting device emitting a light beam and an optical microcavity housing said light emitting device. The optical microcavity is comprised of a plurality of reflective surfaces to specifically manipulate and tune said light beam, wherein one or more of said reflective surfaces is a light propagating reflective surface which propagates said light beam out of said microcavity, and said light propagating reflective surface is connected to said one or more directional optical guiding surfaces to direct said light beam at a specific angle. A high-angular resolution, multiple-view light-field display is created by deploying a plurality of directional pixels into a directional pixel array system.
-
2.发明申请INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 审中-公开用于定向递送至表达VLA-4的细胞的整合拮抗剂
公开(公告)号：WO2013110680A1
公开(公告)日：2013-08-01
申请号：PCT/EP2013/051275
申请日：2013-01-24
Applicant: F. HOFFMANN-LA ROCHE AG , GOODNOW Jr., Robert, Alan , HAMILTON, Matthew, Michael , SIDDURI, Achyutharao
CPC classification number: A61K47/545 , A61K47/54 , A61K47/60
Abstract: The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.
Abstract translation: 本发明涉及式I化合物：其中R1，R2和n在详细描述和权利要求书中定义。 特别地，本发明涉及式I化合物，其用于制备和递送缀合的部分，例如小分子，肽，核酸，荧光部分和与VLA-4整联蛋白拮抗剂连接至靶细胞的聚合物 表达VLA-4。
-
3.发明申请INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING ALPHA-V-BETA-3 审中-公开用于指定递送至表达ALPHA-V-BETA-3的细胞的整合拮抗剂
公开(公告)号：WO2013110578A1
公开(公告)日：2013-08-01
申请号：PCT/EP2013/051082
申请日：2013-01-22
Applicant: F. HOFFMANN-LA ROCHE AG , GOODNOW JR., Robert Alan , HAMILTON, Matthew Michael , KOWALCZYK, Agnieszka , SIDDURI, Achyutharao
Inventor： GOODNOW JR., Robert Alan , HAMILTON, Matthew Michael , KOWALCZYK, Agnieszka , SIDDURI, Achyutharao
CPC classification number: C07D277/593 , A61K47/48061 , A61K47/48092 , A61K47/48215 , A61K47/545 , A61K47/549 , A61K47/60 , C07C237/52 , C07C327/32 , C07D207/452 , C07D239/14 , C07D417/12
Abstract: The invention relates to compounds of formula (I): wherein R 1 , R 2 , and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.
Abstract translation: 本发明涉及式（I）的化合物：其中R 1，R 2和n在详细描述和权利要求书中定义。 特别地，本发明涉及用于制备和递送缀合部分的式（I）化合物，所述共轭部分例如小分子，肽，核酸，荧光部分和与α-V-β- 3整合素拮抗剂靶向表达α-V-β-3的细胞。
-
公开(公告)号：WO2007056341A1
公开(公告)日：2007-05-18
申请号：PCT/US2006/043289
申请日：2006-11-08
Applicant: VERTEX PHARMACEUTICALS INCORPORATED , HADIDA RUAH, Sara , HAMILTON, Matthew , MILLER, Mark , GROOTENHUIS, Peter, D., J. , BEAR, Brian , MCCARTHY, Jason , ZHOU, Jinglan
Inventor： HADIDA RUAH, Sara , HAMILTON, Matthew , MILLER, Mark , GROOTENHUIS, Peter, D., J. , BEAR, Brian , MCCARTHY, Jason , ZHOU, Jinglan
IPC: C07D405/12 , C07D405/14 , C07D213/75 , A61K31/5585 , A61K31/4418 , A61P11/00
CPC classification number: C07D405/12 , A61K31/443 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D405/14
Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Abstract translation: 本发明的化合物及其药学上可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜电导调节剂（“CFTR”）。 本发明还涉及使用本发明化合物治疗ABC转运蛋白介导的疾病的方法。
-
公开(公告)号：WO2011057956A1
公开(公告)日：2011-05-19
申请号：PCT/EP2010/066857
申请日：2010-11-05
Applicant: F. HOFFMANN-LA ROCHE AG , BOLIN, David, Robert , HAMILTON, Matthew, Michael , MCDERMOTT, Lee, Apostle , QIAN, Yimin
IPC: C07D261/20 , C07D403/12 , A61P3/10 , A61K31/423
CPC classification number: C07D261/20 , C07D403/12
Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
Abstract translation: 本文提供式（I）的化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗代谢疾病和病症，例如II型糖尿病。
-
Patent Agency Ranking
公开(公告)号：WO2010056506A1
公开(公告)日：2010-05-20
申请号：PCT/US2009/062154
申请日：2009-10-27
Applicant: VIA PHARMACEUTICALS, INC. , BOLIN, David, R. , CHEUNG, Adrian, Wai-hing , HAMILTON, Matthew, Michael , MARCOPULOUS, Nicholas , McDERMOTT, Lee, Apostle , QIAN, Yimin
Inventor： BOLIN, David, R. , CHEUNG, Adrian, Wai-hing , HAMILTON, Matthew, Michael , MARCOPULOUS, Nicholas , McDERMOTT, Lee, Apostle , QIAN, Yimin
IPC: C12Q1/48
CPC classification number: C07D401/04 , C07D213/75 , C07D213/82 , C07D277/46 , C07D277/82 , C07D295/155 , C07D295/185 , C07D295/205 , C07D333/54 , C07D401/12
Abstract: Provided herein are compounds of the formula (I): were Rl is phenyl, R2 is hyrogen, halogen or lower alkyl,X is carbon on nitrogen, and R3 is isoquinoline, -amino, or a-4- to 6-membered heterocycloalkyl ring and pharmaceutically acceptable salts thereof, which are active as DGAT inhibitors and therefore find uses in treatment of diseases associated with abnormal metabolism of triglicerides, such as, for example, obesity, type Il diabetes mellitus and metabolic syndrome.
Abstract translation: 本文提供了式（I）的化合物：R1是苯基，R2是氢，卤素或低级烷基，X是氮上的碳，R3是异喹啉， - 氨基或a-4-至6-元杂环烷基环 其药学上可接受的盐，其作为DGAT抑制剂是有活性的，因此可用于治疗与三联嘧啶的异常代谢相关的疾病，例如肥胖症，II型糖尿病和代谢综合征。
-
公开(公告)号：WO2005026137A3
公开(公告)日：2005-07-21
申请号：PCT/US2004029206
申请日：2004-09-07
Applicant: VERTEX PHARMA , MILLER MARK T , HADIDA RUAH SARA S , SINGH ASHAVINI K , CLEVELAND THOMAS , MAKINGS LEWIS R , HAMILTON MATTHEW , GROOTENHUIS PETER D J
Inventor： MILLER MARK T , HADIDA RUAH SARA S , SINGH ASHAVINI K , CLEVELAND THOMAS , MAKINGS LEWIS R , HAMILTON MATTHEW , GROOTENHUIS PETER D J
IPC: A61K31/426 , A61K31/427 , A61P43/00 , C07D263/48 , C07D277/46 , C07D277/82 , C07D417/02 , C07D417/04 , C07D417/06 , C07D417/12
CPC classification number: A61K31/426 , A61K31/4439 , A61K31/454 , A61K31/5377 , C07D263/48 , C07D277/46 , C07D277/82 , C07D295/15 , C07D417/04 , C07D417/06 , C07D417/12 , G01N33/5076
Abstract: The present invention relates to modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including CF Transmembrane Regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
Abstract translation: 本发明涉及ATP结合盒（“ABC”）转运体或其片段的调节剂，包括CF跨膜调节剂（“CFTR”），其组合物及其方法。 本发明还涉及使用这种调节剂治疗ABC转运蛋白介导的疾病的方法。
-
公开(公告)号：WO2017127067A1
公开(公告)日：2017-07-27
申请号：PCT/US2016/014078
申请日：2016-01-20
Applicant: VALDERRABANO, Victor , NUNLEY, James , DEORIO, James , EASLEY, Mark , HAMILTON, Matthew , DIEP, Phong
Inventor： VALDERRABANO, Victor , NUNLEY, James , DEORIO, James , EASLEY, Mark , HAMILTON, Matthew , DIEP, Phong
IPC: A61F2/42
CPC classification number: A61F2/4202 , A61F2002/30878 , A61F2002/30934 , A61F2002/4207
Abstract: A talar implant, comprising: a superior surface, defined by an arc having at least one first radius; an inferior surface, defined by an arc having at least one second radius, a lateral side; a medial side; a posterior portion having a first width; and an anterior portion having a second width; wherein the implant is configured to restore a tibio-talar joint tension, wherein the superior surface is separated from the inferior surface by a thickness, wherein the at least one first radius is smaller than the at least one second radius, wherein the center of the arc having at least one first radius is offset from the center of the arc having at least one second radius in at least one plane of the talar implant, and wherein the anterior portion further comprises an extension configured to provide support.
Abstract translation: 一种距骨植入物，其包括：上表面，其由具有至少一个第一半径的弧限定; 由具有至少一个第二半径的弧限定的下表面;外侧; 内侧; 具有第一宽度的后部; 和具有第二宽度的前部部分; 其中所述植入物被构造成恢复胫骨关节张力，其中所述上表面与所述下表面分开一定厚度，其中所述至少一个第一半径小于所述至少一个第二半径，其中所述 具有至少一个第一半径的圆弧在距骨植入物的至少一个平面中从具有至少一个第二半径的圆弧的中心偏移，并且其中前部还包括构造成提供支撑的延伸部。
-
公开(公告)号：WO2008141976A1
公开(公告)日：2008-11-27
申请号：PCT/EP2008/055843
申请日：2008-05-13
Applicant: F. HOFFMANN-LA ROCHE AG , BOLIN, David Robert , CHEUNG, Adrian Wai-Hing , FIROOZNIA, Fariborz , HAMILTON, Matthew Michael , MCDERMOTT, Lee Apostle , QIAN, Yimin , TAN, Jenny , YUN, Weiya
Inventor： BOLIN, David Robert , CHEUNG, Adrian Wai-Hing , FIROOZNIA, Fariborz , HAMILTON, Matthew Michael , MCDERMOTT, Lee Apostle , QIAN, Yimin , TAN, Jenny , YUN, Weiya
IPC: C07D231/14 , C07D263/34 , C07D277/56 , C07D307/68 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14 , A61K31/422 , A61K31/427 , A61K31/4178 , A61K31/4192 , A61K31/4427
CPC classification number: C07D263/34 , C07D231/14 , C07D277/56 , C07D307/68 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
Abstract translation: 本文提供式（I）化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗疾病，例如肥胖症，II型糖尿病和代谢综合征。
-
公开(公告)号：WO2008140810A1
公开(公告)日：2008-11-20
申请号：PCT/US2008/006046
申请日：2008-05-09
Applicant: CYTOKINETICS, INCORPORATED , BASKARAN, Chitra , HAMILTON, Matthew R. , COLLIBEE, Scott , WANG, Jianchao , ASHCRAFT, Luke W. , MARIN, Melchor , AHMAD, Seyed , YANG, Zhe , YAO, Bing , JIANG, Hong , QIAN, Xiangping , MORGAN, Bradley P. , BERGNES, Gustave
Inventor： BASKARAN, Chitra , HAMILTON, Matthew R. , COLLIBEE, Scott , WANG, Jianchao , ASHCRAFT, Luke W. , MARIN, Melchor , AHMAD, Seyed , YANG, Zhe , YAO, Bing , JIANG, Hong , QIAN, Xiangping , MORGAN, Bradley P. , BERGNES, Gustave
IPC: A61K31/355
CPC classification number: C07D211/60 , C07D211/32 , C07D211/58 , C07D241/04 , C07D401/04 , C07D401/06 , C07D401/14 , C07D453/02
Abstract: Selected substituted piperidyl compounds as pharmaceutical compositions, to treat antiproliferative diseases are disclose It is of particular interest to develop agents with improved specificity and fewer side effects as antiproliferative agents. The pharmaceutical compositions of the subject invention encompass a kit for treating cancer.
Abstract translation: 公开了用于治疗抗增殖性疾病的选择性取代的哌啶基化合物作为药物组合物。开发具有改善的特异性的试剂和作为抗增殖剂的副作用较少是特别有意义的。 本发明的药物组合物包括用于治疗癌症的试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.02 seconds)
